Certain mutations likely to be associated with poor clinical outcomes showed a decent performance across multiple cancer types, notable examples being those harbored by TP53, BAP1, MTOR, and GNAS. The relatively high and consistent performance observed for TP53 might be attributed to tumors with TP53 mutations likely being poorly differentiated, and exhibiting visually discernible higher-grade cell changes15. This evidence concerns the gene GNAS and cancer.